Evidence map›Paper›PMID 39968520›Full record

ArticleToxicology research2025

Mechanisms of ARA290 in counteracting cadmium-triggered neurotoxicity in PC12 cells.

Farzaneh Motafeghi, Maryam S Fakhri B, Nasrin Ghassemi Barghi

Abstract read
In one paragraph

Article in Toxicology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Farzaneh MotafeghiReproductive Endocrinology Research Center, Research Institute for Endocrine Molecular Biology, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tajrish, Taleqani St, No. 24, P.O. Box 19395-4763, Tehran, Iran.ORCID https://orcid.org/0000-0001-5756-7575
Maryam S Fakhri BToxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), Tehran University of Medical Sciences, District 6, Pour Sina St, P94+V8MF, Tehran Province, Tehran, Iran.
Nasrin Ghassemi BarghiToxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), Tehran University of Medical Sciences, District 6, Pour Sina St, P94+V8MF, Tehran Province, Tehran, Iran.ORCID https://orcid.org/0000-0002-0673-4262

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Erythropoietin (EPO) is known for its role in hematopoiesis and also exhibits anti-inflammatory, anti-apoptotic, antioxidant, and cytoprotective properties. However, its clinical application is limited by hematopoietic side effects. ARA290, a non-hematopoietic derivative of EPO, selectively activates the innate repair receptor (IRR) and replicates these protective effects without the associated hematopoietic complications. Cadmium (Cd), a prevalent environmental toxin, causes neurotoxic damage through mechanisms such as oxidative stress, genotoxicity, apoptosis, and inflammation. This study explored ARA290's neuroprotective effects against cadmium-induced toxicity in PC12 cells, an in vitro model for neuronal health. PC12 cells pretreated with ARA290 showed significantly improved cell viability in the MTT assay, indicating reduced cytotoxicity. The comet assay revealed decreased DNA damage, suggesting reduced genotoxicity. ARA290 also alleviated oxidative stress, as evidenced by reduced levels of reactive oxygen species (ROS) and malondialdehyde (MDA), alongside increased glutathione (GSH), total antioxidant capacity (TAC), and superoxide dismutase (SOD) activities. A marker of apoptosis, TUNEL-positive cells, was significantly reduced. Additionally, ARA290 decreased inflammatory markers such as TNF alpha, IL1ß and IL 6. These findings demonstrate that ARA290, via IRR activation, provides robust neuroprotection against cadmium-induced toxicity, suggesting a multi-faceted protective mechanism. This highlights ARA290's potential therapeutic role in managing heavy metal-induced neurotoxicity and supports further research into its long-term effects and applications in other neurodegenerative diseases or conditions involving environmental toxins. Highlights: ARA290 as a Neuroprotective Agent: ARA290, a modified form of erythropoietin that doesn't affect blood production, shows promising neuroprotective effects. It helps counteract the harmful effects of cadmium exposure on nerve cells by reducing oxidative stress, inflammation, cell death, and DNA damage.Reducing Oxidative Stress: ARA290 plays a key role in lowering oxidative stress by cutting down on harmful molecules like reactive oxygen species (ROS) and malondialdehyde (MDA). At the same time, it boosts the body's natural antioxidant defenses, including glutathione (GSH), superoxide dismutase (SOD), and overall antioxidant capacity.Protecting DNA Integrity: By reducing DNA damage caused by cadmium, ARA290 helps preserve the genetic stability of nerve cells. This protective effect is evident in laboratory tests, where it lowers the extent of DNA damage seen in the comet assay.Fighting Inflammation and Cell Death: ARA290 also has strong anti-inflammatory and anti-apoptotic effects. It reduces levels of inflammation markers like TNF-α, IL-1β, and IL-6, and significantly cuts down on nerve cell death, as seen in fewer TUNEL-positive cells in experiments.A Therapeutic Promise: Overall, these findings underscore ARA290's ability to protect the nervous system through multiple pathways. This makes it a promising candidate for treating cadmium-induced nerve damage and potentially other neurodegenerative conditions.

Indexed as

ARA290cadmiumGenotoxicityinflammationneurotoxicityPC12

Identifiers

PMID39968520
PMCPMC11831023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.